Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. CytomX Therapeutics Inc shares valued at $22,556 were sold by McCarthy Sean A. on Mar 18 ’25. At $0.60 per share, McCarthy Sean A. sold 37,656 shares. The insider’s holdings dropped to 995,195 shares worth approximately $2.12 million following the completion of this transaction.
Also, Ogden Christopher sold 8,551 shares, netting a total of over 5,122 in proceeds. Following the sale of shares at $0.60 each, the insider now holds 201,026 shares.
Before that, Chu Yu-Waye had sold 4,025 shares from its account. In a trade valued at $2,411, the Chief Medical Officer traded CytomX Therapeutics Inc shares for $0.60 each. Upon closing the transaction, the insider’s holdings decreased to 4,025 shares, worth approximately $0.29 million.
As published in a research note from H.C. Wainwright on May 15, 2025, CytomX Therapeutics Inc [CTMX] has been rated up from a Neutral to a Buy and the price target has been revised to $5. As of May 28, 2024, Piper Sandler has increased its “Neutral” rating to a “an Overweight” for CTMX. Earlier on May 09, 2024, Wedbush upgraded its rating. Their new recommendation was “an Outperform” for CTMX stock which previously was a “a Neutral”.
Analyzing CTMX Stock Performance
During the last five days, there has been a surge of approximately 6.50%. Over the course of the year, CytomX Therapeutics Inc shares have jumped approximately 106.80%. Shares of the company reached a 52-week high of $2.55 on 05/13/25 and a 52-week low of $0.40 on 04/07/25.
Support And Resistance Levels for CytomX Therapeutics Inc (CTMX)
According to the 24-hour chart, there is a support level at 2.01, which, if violated, would cause prices to drop to 1.90. In the upper region, resistance lies at 2.24. The next price resistance is at 2.35. RSI (Relative Strength Index) is 69.80 on the 14-day chart, showing neutral technical sentiment.
